Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

ClinicalTrials.gov ID: NCT02126839

Public ClinicalTrials.gov record NCT02126839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is to evaluate the chronic-dose efficacy and the safety of Albuterol MDPI compared to placebo in pediatric participants with asthma.

Study identification

NCT ID
NCT02126839
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
186 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
4 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Jan 31, 2015
Completion
Jan 31, 2015
Last update posted
Nov 8, 2021

2014 – 2015

United States locations

U.S. sites
51
U.S. states
21
U.S. cities
48
Facility City State ZIP Site status
Teva Investigational Site 12496 Birmingham Alabama
Teva Investigational Site 12500 Mobile Alabama
Teva Investigational Site 12481 Little Rock Alaska
Teva Investigational Site 12515 Anaheim California
Teva Investigational Site 12505 Costa Mesa California
Teva Investigational Site 12476 Huntington Beach California
Teva Investigational Site 12519 Los Angeles California
Teva Investigational Site 12484 Mission Viejo California
Teva Investigational Site 12510 Riverside California
Teva Investigational Site 12483 Rolling Hills Estates California
Teva Investigational Site 12511 Sacramento California
Teva Investigational Site 12485 Stockton California
Teva Investigational Site 12512 Centennial Colorado
Teva Investigational Site 12522 Gainesville Florida
Teva Investigational Site 12535 Hollywood Florida
Teva Investigational Site 12526 Miami Florida
Teva Investigational Site 12516 Orlando Florida
Teva Investigational Site 12517 Tamarac Florida
Teva Investigational Site 12527 Vero Beach Florida
Teva Investigational Site 12513 Winter Park Florida
Teva Investigational Site 12486 Gainesville Georgia
Teva Investigational Site 12497 Lawrenceville Georgia
Teva Investigational Site 12480 Savannah Georgia
Teva Investigational Site 12508 Shiloh Illinois
Teva Investigational Site 12518 Iowa City Iowa
Teva Investigational Site 12523 Covington Louisiana
Teva Investigational Site 12495 Warrensburg Missouri
Teva Investigational Site 12509 Northfield New Jersey
Teva Investigational Site 12524 Brooklyn New York
Teva Investigational Site 12473 Raleigh North Carolina
Teva Investigational Site 12477 Cincinnati Ohio
Teva Investigational Site 12525 Cleveland Ohio
Teva Investigational Site 12502 Middleburg Heights Ohio
Teva Investigational Site 12478 Oklahoma City Oklahoma
Teva Investigational Site 12487 Oklahoma City Oklahoma
Teva Investigational Site 12506 Oklahoma City Oklahoma
Teva Investigational Site 12492 Tulsa Oklahoma
Teva Investigational Site 12507 Gresham Oregon
Teva Investigational Site 12501 Normal Square Pennsylvania
Teva Investigational Site 12493 Pittsburgh Pennsylvania
Teva Investigational Site 12488 Upland Pennsylvania
Teva Investigational Site 12514 Greenville South Carolina
Teva Investigational Site 12474 Orangeburg South Carolina
Teva Investigational Site 12479 Spartanburg South Carolina
Teva Investigational Site 12489 Boerne Texas
Teva Investigational Site 12475 Waco Texas
Teva Investigational Site 12491 Burke Virginia
Teva Investigational Site 12504 Charlottesville Virginia
Teva Investigational Site 12482 Richmond Virginia
Teva Investigational Site 12498 Richmond Virginia
Teva Investigational Site 12490 Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02126839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02126839 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →